Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/5/2026

1. LULU
2. ZS
3. IOT
4. SPY
5. PATH

6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Get Alerts ABUS Hot Sheet

Price: $5.15 +0.59%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: +50.0%

Join SI Premium – FREE

WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, will participate in the Hepatitis B Functional Cure Panel at the B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:50 am – 10:50 am ET in New York.

About ArbutusArbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors

Mark MurrayPresident and CEOPhone: 604-419-3200 Email: [email protected]

Pam Murphy Investor Relations ConsultantPhone: 604-419-3200Email: [email protected]